6. Americans spend less time waiting for care than patients in Canada and the United Kingdom. Canadian and British patients wait about twice as long—sometimes more than a year—to see a specialist, have elective surgery such as hip replacements, or get radiation treatment for cancer. All told, 827,429 people are waiting for some type of procedure in Canada. In Britain, nearly 1.8 million people are waiting for a hospital admission or outpatient treatment.
7. People in countries with more government control of health care are highly dissatisfied and believe reform is needed. More than 70 percent of German, Canadian, Australian, New Zealand, and British adults say their health system needs either “fundamental change” or “complete rebuilding.”
8. Americans are more satisfied with the care they receive than Canadians. When asked about their own health care instead of the “health care system,” more than half of Americans (51.3 percent) are very satisfied with their health care services, compared with only 41.5 percent of Canadians; a lower proportion of Americans are dissatisfied (6.8 percent) than Canadians (8.5 percent).
9. Americans have better access to important new technologies such as medical imaging than do patients in Canada or Britain. An overwhelming majority of leading American physicians identify computerized tomography (CT) and magnetic resonance imaging (MRI) as the most important medical innovations for improving patient care during the previous decade—even as economists and policy makers unfamiliar with actual medical practice decry these techniques as wasteful. The United States has thirty-four CT scanners per million Americans, compared to twelve in Canada and eight in Britain. The United States has almost twenty-seven MRI machines per million people compared to about six per million in Canada and Britain.
10. Americans are responsible for the vast majority of all health care innovations. The top five U.S. hospitals conduct more clinical trials than all the hospitals in any other developed country. Since the mid- 1970s, the Nobel Prize in medicine or physiology has gone to U.S. residents more often than recipients from all other countries combined. In only five of the past thirty-four years did a scientist living in the United States not win or share in the prize. Most important recent medical innovations were developed in the United States.
With the onset of the new president-elect Barack Obama accelerating toward the driver’s seat of democratically controlled Congress, conservatives cannot help but brace themselves for the sweeping reversal of many of Bush’s policies – particularly in regard to stem cell research. Parties on both sides of the aisle expect Obama to issue an executive order ending the government federal funding ban on embryonic stem cell (ESC) research.
With as much progress stem cell research has achieved, applying the brakes to this Bush policy will detrimentally alter forthcoming advancements. Moral issues aside, ESC research has been spinning in a rut since its inception. Fueling its “development” with federal funding will merely exacerbate the problem.
After nearly a decade, human ESC research is much like the wizard in Dorothy’s Oz: facially powerful, substantively empty. With the promise being a virtual panacea, consider the results: there have been zero treatments and zero clinical trials. Total cost: billions. The continuous mantra chanted by its advocates still sounds, “more time.” California committed $3 billion in tax-payer monies over 10 years with the goal of developing a single treatment. Connecticut and Maryland have invested millions as well. They still have virtually nothing to show.
Consider the alternative: adult stem cells have treated over 80 diseases with over 1,300 clinical trials. Advancements in cord blood banking, and induced pluripotent stem cells are leading the way in medical breakthroughs. Recently, European physicians completed the first successful transplant of a human windpipe using (you guessed it) adult stem cells. Plenty more could be said of treatments for leukemia, diabetes, sickle-cell anemia and heart disease.
The government should support what works; it makes common financial sense: invest in known, proven, un-problematic means to advance medicine for a guaranteed rate of return. But channeling that money into decade-long speculation without proven results serves to limit development in medical pioneering. It is essentially pork barrel spending.
ESC research is by no means limited as a “moral” issue. An executive order subsidizing this research merely feeds the white elephant.